{
    "nct_id": "NCT05272150",
    "official_title": "A Phase 3b, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Safety and Efficacy of Guselkumab for the Treatment of Participants With Skin of Color Who Have Moderate-to-Severe Plaque Psoriasis and/or Moderate-to-Severe Scalp Psoriasis",
    "inclusion_criteria": "* Have a diagnosis of plaque psoriasis (with or without psoriatic arthritis [PsA]) for at least 6 months before the first administration of study drug\n* Self-identify as non-white or non-caucasian\n* Be a candidate for phototherapy or systemic treatment for psoriasis\n* Have an involved body surface area (BSA) greater than or equal to (>=) 10 percent (%), psoriasis area and severity index (PASI) >=12, investigator global assessment (IGA) >=3 at screening and at baseline (Cohort A), or have a scalp surface area >=30%, psoriasis scalp severity index (PSSI) >=12, scalp specific investigator global assessment (ss-IGA) >=3, and one plaque outside of the scalp at screening and at baseline (Cohort B)\n* Agree not to receive a live virus or live bacterial vaccination during the study, or within 12 weeks after the last administration of study intervention\n* Agree not to receive a Bacillus Calmette-Gu√©rin (BCG) vaccination during the study, and within 12 weeks after the last administration of study intervention\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Has a nonplaque form of psoriasis (example: erythrodermic, guttate, or pustular)\n* Has received ustekinumab, ixekizumab, secukinumab, or brodalumab within 12 weeks of first dose of study drug\n* Has a history or current signs or symptoms of severe, progressive, or uncontrolled renal, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances\n* Participant has known allergies, hypersensitivity, or intolerance to guselkumab or its excipients\n* Has or has had a serious infection (example: sepsis, pneumonia or pyelonephritis), or has been hospitalized or received intravenous antibiotics for an infection during the 2 months before screening",
    "miscellaneous_criteria": ""
}